Skip to content

Clovertex Target of the Month (05/24): FZD4

This May's Clovertex Target of the Month is the FZD4 Receptor, a pivotal protein involved in Wnt signaling pathways crucial for various cellular processes including cell proliferation, differentiation, and migration. The FZD4 receptor is notably significant in eye diseases, where it plays a central role in maintaining retinal vascular integrity. Targeting FZD4 is therefore a strategic focus for new therapies in ophthalmology, particularly for retinal diseases.

The selection of FZD4 as the Target of the Month follows news of a major acquisition deal between Merck and EyeBio for up to $3 billion. Merck agreed to purchase the privately held biotech giving it access to EyeBio’s retinal disease drug, Restoret, which specifically targets the FZD4 receptor.  This deal includes an upfront payment of $1.3 billion in cash and potential future milestone payments of up to $1.7 billion.


The Protein Imager rendering displays the crystal structure of human apo-Frizzled4 receptor (PDB entry 6BD4).  

About Clovertex

Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.

Useful links

1. Merck to buy eye-focused drug developer EyeBio for as much as $3 bln

2. Clovertex website